Recent Hologic Acquisition Bolder Surgical Included on Fast Company’s Annual List of World’s Most Innovative Companies

Company Recognized for Pioneering Advanced Energy Vessel Sealing Surgical Devices, Including Hologic's CoolSeal® Vessel Sealing Portfolio

Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that recently acquired Bolder Surgical was included on Fast Company’s annual list of the World’s Most Innovative Companies. Bolder Surgical, a developer and manufacturer of advanced energy vessel sealing and dissection tools for surgical gynecologists in both laparoscopic and open procedures was acquired by Hologic in November 2021.

Hologic notes Bolder ranked fifth on the list of Most Innovative Medical Device Companies, a sector highlighting companies that are creatively using technology to improve patient care. The full list of Most Innovative Companies consisted of 528 companies chosen by a team of editors and reporters for Fast Company from thousands of applicants across the globe.

“We’re thrilled that Bolder — the newest member of our Surgical business — has captured a spot on Fast Company’s prestigious list of the most innovative companies making an impact around the globe,” said Essex Mitchell, Hologic’s Division President, Surgical. “The CoolSeal devices have already proven to be an important addition to our growing Surgical portfolio, and we’re looking forward to seeing how we can continue to improve efficiency for surgeons and hospitals, while helping to improve outcomes for patients, through these innovative products.”

Bolder was recognized for its innovation in designing surgical devices, in particular the CoolSeal® devices, which allows for dissection, vessel sealing and dividing all in one tool. The ability to use a combination device improves surgical efficiency by reducing the need for instrument exchanges. In addition, Bolder’s CoolSeal® Mini 3 mm vessel sealer and the JustRight® 5 mm stapler are designed for small surgical spaces such as in pediatric cases, which can help reduce the need for larger, overpowered instruments.

Hologic’s surgical product line also includes the NovaSure® endometrial ablation system for the treatment of abnormal uterine bleeding, the MyoSure® tissue removal devices for the removal of intrauterine fibroids and polyps, the Acessa® laparoscopic radiofrequency ablation system for the treatment of fibroids, and the Fluent® fluid management system for streamlining hysteroscopic procedures.

According to Fast Company, the Most Innovative Companies list “has been the definitive source for recognizing the organizations that are transforming industries and shaping society” since it began in 2008.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.